Sign in

CIK 0001737287

  • Non-accelerated filer
  • Smaller reporting company

Allogene Therapeutics, Inc.

Sign in to watch
Ticker
ALLO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
823562771
Phone
+1 650-457-2700
Business address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale EVP of R&D sold 35,700 shares at $1.77 ($63,189)
  2. 4 Derivatives Options or other derivatives
  3. 4 Open-market sale EVP of R&D sold 26,269 shares at $1.56 ($40,980)
  4. 4 Option exercise Director acquired 47,700 shares (option exercise)
  5. 4 Open-market sale SVP, Chief Technical Officer sold 786 shares at $1.22 ($959)
  6. 4 Open-market sale CHIEF FINANCIAL OFFICER sold 36,744 shares at $1.26 ($46,169)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Planned sale Director sold 36,885 shares at $1.42 ($52,377)
  15. 4 Open-market sale SVP, Finance sold 9,601 shares at $1.41 ($13,537)
  16. 4 Open-market sale President and CEO sold 46,668 shares at $1.96 ($91,469)
  17. 4 Open-market sale SVP, Chief Technical Officer sold 5,488 shares at $1.98 ($10,839)
  18. 4 Grant or award SVP, Chief Technical Officer acquired 31,755 shares (grant or award)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Planned sale Director sold 13,313 shares at $2.43 ($32,351)

Page 2 of 14 · 275 filings